AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (220 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Letter | Open Access

Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: a retrospective real-world analysis

Yang Liu1,2,*, Dandan Wu1,*, Xing Li3,4,*, Xihao Zhang2, Rentao Li2, Yanmei Ou4, Hao Wang1, Tongguo Si5,6, Rui Xia7,8, Yong Xu3,4, Huikai Li1,2 ( ), Chuntao Gao2,9 ( ), Jihui Hao2,9 ( )
Department of Hepatobiliary Cancer, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Hepatobiliary and Pancreatic Oncology, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China
Department of Ultrasound Diagnosis and Treatment, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Ultrasound Diagnosis and Treatment, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China
Department of Interventional Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Interventional Therapy, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China
Intensive Care Unit, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Intensive Care Unit, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China
Department of Pancreatic Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China

*These authors contributed equally to this work.

Show Author Information

Electronic Supplementary Material

Download File(s)
cbm-23-6-946_ESM.pdf (425 KB)

References

【1】
【1】
 
 
Crossref Google Scholar
Cancer Biology & Medicine
Volume 23 Issue 6,
June 2026
Pages 946-950
DOI: 10.20892/j.issn.2095-3941.2025.0848

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Cite this Report
Close
Close
Cite this article:
Liu Y, Wu D, Li X, et al. Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: a retrospective real-world analysis. Cancer Biology & Medicine, 2026, 23(6): 946-950. https://doi.org/10.20892/j.issn.2095-3941.2025.0848

17

Views

0

Downloads

0

Crossref

0

Web of Science

0

Scopus
Received: 13 January 2026
Accepted: 25 February 2026
Published: 16 March 2026
©2026 The Authors.

Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)